Exposure–Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation Recipients. Issue 2 (29th November 2021)

• Record Type: Journal Article
• Authors: Prohn, Marita; Cho, Carolyn R.; Viberg, Anders; Dykstra, Kevin; Davis, Casey; Sabato, Philip; Stone, Julie; Badshah, Cyrus; Murata, Yoshihiko; Leavitt, Randi; Fancourt, Craig; Macha, Sreeraj
• Is Part Of: Clinical pharmacology & therapeutics. Volume 111:Issue 2(2022)
• Page Start: 485
• Page End: 495
• Publication Date: 2021-11-29
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1002/cpt.2456
• Languages: English
• ISSNs: 0009-9236

Abstract

Abstract : The cytomegalovirus (CMV) viral terminase inhibitor letermovir is approved for prophylaxis of CMV infection and disease in adult CMV‐seropositive allogeneic hematopoietic stem cell transplantation recipients. In a phase III trial (NCT02137772), letermovir significantly reduced clinically significant CMV infection (CS‐CMVi) rate vs. placebo through Week 24 (primary end point) and Week 14 (secondary end point) post transplantation. Here, exposure–response relationships were investigated using efficacy and selected safety end points from the phase III trial to inform the proposed clinical dose. Post hoc exposure estimates were derived from a population pharmacokinetic model. No significant exposure dependencies were found for CS‐CMVi through Week 24 or Week 14 among letermovir‐treated participants. Evaluated covariates had no impact on exposure–efficacy relationships and letermovir plasma exposure did not affect time of CS‐CMVi onset. There was no dependence between adverse event incidence and letermovir exposure. These results support current dosing recommendations in several countries and regions, including the United States and European Union.